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COST-EFFECTIVENESS OF PRAMIPEXOLE IN 
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2Centocor, Inc., Malvern, PA, US; 3Boehringer Ingelheim 
Pharmaceuticals, Inc., Ridgefield, CT, US; 4Pharmacia & Upjohn, 
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OBJECTIVES: A pharmacoeconomic model is used to es-
timate the costs and cost-effectiveness of treating Parkin-
son’s disease patients with pramipexole in Canada, Ger-
many, and Sweden.
METHODS: We developed a cost-effectiveness model
that linked Unified Parkinson’s Disease Rating Scale
(UPDRS) Part II (ADL) and III (Motor) scores to disease
progression, costs, and quality-adjusted life years (QALYs).
Data were obtained from clinical trials, literature review,
and a survey of 193 patients’ resource use and health util-
ity. Country-specific data on treatment patterns were col-
lected using panels of physician experts in each country.
Cost and QALY estimates from the model were used to
estimate the incremental cost-effectiveness of pramipex-
ole relative to baseline treatment. Separate analyses were
performed for early and advanced Parkinson’s patients.
Extensive sensitivity analyses were performed.
RESULTS: In Canada and Germany, treatment with
pramipexole has higher costs but is more effective than
baseline treatment. In Sweden, treatment with pramipexole
has lower costs and is more effective than baseline treat-
ment. The incremental cost-effectiveness ratios for early
patients in Canada, Germany, and Sweden are $CDN
28,097, DM 26,780, and -SEK 41,161, respectively (in
1997 currency). For advanced patients, the corresponding
ratios are $CDN 25,090, DM 49,168, and -SEK 27,386.
These ratios are lower than the cost-effectiveness ratios of
many widely used medical treatments. 
CONCLUSIONS: Subject to the inherent limitations of
modeling chronic disease progression and subsequent
health utility and costs, the results indicate that prami-
pexole is a cost-effective treatment for early and ad-
vanced Parkinson’s disease patients in Canada, Germany,
and Sweden.
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IPRATROPIUM SOLUTION
LeLorier J1, Blais L1, Castilloux A-M1, Renzi P1, Miller B2
1Centre de recherche, Centre hospitalier de l’Université de 
Montréal, Campus Hôtel-Dieu, Canada; 2Boehringer Ingelheim 
Ltd., Burlington, Ontario, Canada
BACKGROUND: There has been an important increase
in the use of nebulized ipratropium solution (NIS) in the
ambulatory treatment of elderly patients with chronic air-
way disease. Since these are relatively expensive medica-
tions, it is important to define the characteristics and the
natural history of the patients who are started on this
therapy and compare them with those of the patients
started on ipratropium metered dose inhalers (IMDI) or
oral theophylline (OT).
METHODS: The Quebec health insurance program
(RAMQ) database was used for the study. The index date
was the first dispensation of NIS (n  761), IMDI (n 
3870), or OT (n  10355). The consumption of drugs
and medical services was measured during the 12 months
before the index date.
RESULTS: At the time therapy was initiated, patients
started on NIS had had more hospitalization days for
chronic airway disease (NIS: 2.97, IMDI: 0.92, OT:
0.12). They were also much heavier users of beta-agonists
(NIS: 13.53, IMDI: 4.9, OT: 0.11) and inhaled cortico-
steroids (NIS: 4.63, IMDI: 2.1, OT: 0.37). The fact that
patients started on NIS had a more advanced form of
chronic airway disease was confirmed by their much
higher mortality rates (percent and 95% CI) during the
12 months following their index date (NIS: 17.2 [14.3–
20.1], IMDI: 8.3 [7.5–9.1], OT: 4.9 [4.6–5.3]).
CONCLUSION: Patients are started on NIS when they
have reached a very advanced form of their disease, as
shown by their high mortality rates and extremely heavy
use of beta-agonists.
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THE EFFECT OF AGE ON COST-EFFECTIVENESS 
IN THE TREATMENT OF MODERATE ASTHMA
Kielhorn A, Behrens M
Glaxo Wellcome GmbH & Co., Hamburg, Germany
OBJECTIVE: The aim of this work is to identify the ef-
fect of age on cost-effectiveness in the treatment of mod-
erate asthma patients with inhaled corticosteroids.
METHODS: The cost-effectiveness analysis was con-
ducted as a retrospective analysis of clinical trial data.
The data of one open and one double-blind multicenter,
parallel group study comparing the efficacy of Flutica-
sone and Flunisolide were pooled. The pooled intent-to-
treat (ITT) group consisted of 308 patients. Because of
the retrospective nature of the study, only the costs of
treatment medication and of concomitant medication
were included. No hospital admissions occurred. The ad-
verse event costs were identified as negligible and there-
fore omitted. Because physicians’ visits were protocol
driven, they were also excluded. Effectiveness (success-
fully treated patients) was defined by an increase in peak
flow of 5% or more. Total treatment costs for each age
group were calculated and divided over the number of
patients fulfilling the effectiveness criterion.
RESULTS: Total average daily treatment costs per pa-
tient were DM 4.58 (sd  DM 1.61). The average cost-
effectiveness ratio per successfully treated patient was
DM 7.84 (sd  DM 1.72). The cost-effectiveness ratios
